--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-26-068774" form_type: "8-K" ticker: "TARA" cik: "0001359931" company_name: "Protara Therapeutics, Inc." filed_at: "2026-06-15T20:05:37+00:00" generated_at: "2026-06-15T20:12:37.168500+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.4 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Protara shareholders vote to double authorized shares to 200M at annual meeting ## Summary - Authorized common stock increased from 100M to 200M shares; 42.4M for, 2.7M against. - Class III directors elected: Jesse Shefferman, Barry Flannelly, Cynthia Smith. - Advisory say-on-pay approved (29.2M for); frequency set to every 1 year (26.8M for). - Amendment to 2024 Equity Incentive Plan approved (18.1M for, 12.8M against). - Officer exculpation amendment passed (29.6M for, 1.2M against). ## SEC filing metadata - accession: 0001213900-26-068774 - form_type: 8-K - ticker: TARA - cik: 0001359931 - company_name: Protara Therapeutics, Inc. - filed_at: 2026-06-15T20:05:37+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.4 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/ea0294030-8k_protara.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-26-068774 - JSON: https://secwatch.observer/filing/0001213900-26-068774.json - Plain text: https://secwatch.observer/filing/0001213900-26-068774.txt ## Key facts - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan at the 2026-06-12 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 5. Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan. The Company’s stockholders approved the amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 18,094,953 12,793,033 25,879 14,185,811 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law at the 2026-06-12 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 7. Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law. The Company’s stockholders approved the amendment to the Company’s sixth amended and restated certificate of incorporation allowing officer exculpation as permitted by Delaware law. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 29,642,641 1,235,007 36,217 14,185,811 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000 at the 2026-06-12 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 6. Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000. The Company’s stockholders approved the amendment to the Company’s sixth amended and restated certificate of incorporation to increase the authorized number of the Company’s common stock, par value $0.001 per share, from 100,000,000 to 200,000,000. The final voting results are as follows: Votes For Votes Against Abstentions 42,417,621 2,655,416 26,639 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-12 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Jesse Shefferman 26,672,259 4,241,606 14,185,811 Barry Flannelly, Pharm.D. 25,409,066 5,504,799 14,185,811 Cynthia Smith 22,371,125 8,542,740 14,185,811 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-06-12 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 29,208,205 1,656,994 48,666 14,185,811 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote at the 2026-06-12 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 4. Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote. The Company’s stockholders voted, on an advisory basis, that the stockholder advisory vote to approve the compensation of the Company’s named executive officers should occur every one year. The final voting results are as follows: One Year Two Years Three Years Abstentions Broker Non-Votes 26,766,824 660,775 3,441,894 44,372 14,185,811 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm - Shareholder Votes Protara Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-12 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-12 source text: Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 45,012,036 74,615 13,025 evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.